146 related articles for article (PubMed ID: 38086333)
1. NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms.
Gerstberger S; Ganesh K
Cancer Cell; 2023 Dec; 41(12):2014-2016. PubMed ID: 38086333
[TBL] [Abstract][Full Text] [Related]
2. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
[TBL] [Abstract][Full Text] [Related]
4. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
Dayton TL; Alcala N; Moonen L; den Hartigh L; Geurts V; Mangiante L; Lap L; Dost AFM; Beumer J; Levy S; van Leeuwaarde RS; Hackeng WM; Samsom K; Voegele C; Sexton-Oates A; Begthel H; Korving J; Hillen L; Brosens LAA; Lantuejoul S; Jaksani S; Kok NFM; Hartemink KJ; Klomp HM; Borel Rinkes IHM; Dingemans AM; Valk GD; Vriens MR; Buikhuisen W; van den Berg J; Tesselaar M; Derks J; Speel EJ; Foll M; Fernández-Cuesta L; Clevers H
Cancer Cell; 2023 Dec; 41(12):2083-2099.e9. PubMed ID: 38086335
[TBL] [Abstract][Full Text] [Related]
5. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
6. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.
Kawasaki K; Toshimitsu K; Matano M; Fujita M; Fujii M; Togasaki K; Ebisudani T; Shimokawa M; Takano A; Takahashi S; Ohta Y; Nanki K; Igarashi R; Ishimaru K; Ishida H; Sukawa Y; Sugimoto S; Saito Y; Maejima K; Sasagawa S; Lee H; Kim HG; Ha K; Hamamoto J; Fukunaga K; Maekawa A; Tanabe M; Ishihara S; Hamamoto Y; Yasuda H; Sekine S; Kudo A; Kitagawa Y; Kanai T; Nakagawa H; Sato T
Cell; 2020 Nov; 183(5):1420-1435.e21. PubMed ID: 33159857
[TBL] [Abstract][Full Text] [Related]
7. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract][Full Text] [Related]
8. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
9. EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms.
Munker S; Vogelhuber M; Bornschein J; Stroszczynski C; Evert M; Schlitt H; Herr W; Teufel A
Z Gastroenterol; 2020 Feb; 58(2):133-136. PubMed ID: 31896137
[TBL] [Abstract][Full Text] [Related]
10. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
Frizziero M; Kilgour E; Simpson KL; Rothwell DG; Moore DA; Frese KK; Galvin M; Lamarca A; Hubner RA; Valle JW; McNamara MG; Dive C
Clin Cancer Res; 2022 May; 28(10):1999-2019. PubMed ID: 35091446
[TBL] [Abstract][Full Text] [Related]
11. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
12. High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.
Motylewska E; Braun M; Stępień H
Endocr Pathol; 2020 Sep; 31(3):264-273. PubMed ID: 32504181
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modifications of histone h4 in lung neuroendocrine tumors.
Li F; Ye B; Hong L; Xu H; Fishbein MC
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):389-94. PubMed ID: 21415707
[TBL] [Abstract][Full Text] [Related]
14. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Dijkstra KK; van den Berg JG; Weeber F; van de Haar J; Velds A; Kaing S; Peters DDGC; Eskens FALM; de Groot DA; Tesselaar MET; Voest EE
Front Endocrinol (Lausanne); 2021; 12():627819. PubMed ID: 33776923
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
17. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
18. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
20. Morphologic and molecular classification of lung neuroendocrine neoplasms.
Metovic J; Barella M; Bianchi F; Hofman P; Hofman V; Remmelink M; Kern I; Carvalho L; Pattini L; Sonzogni A; Veronesi G; Harari S; Forest F; Papotti M; Pelosi G
Virchows Arch; 2021 Jan; 478(1):5-19. PubMed ID: 33474631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
